PE
JANX icon

Point72 Europe’s Janux Therapeutics JANX Stock Holding History

Point72 Europe’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$30.8K Buy
+1,259
New +$30.7K ﹤0.01% 425

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Point72 Europe's JANX Position: Q3 2025 in Review

Point72 Europe opened a new position in Janux Therapeutics (JANX) in Q3 2025: 1,259 shares worth $30.8K. The stake represents ﹤0.01% of the portfolio and ranks #425 among its holdings.

174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Point72 Europe held 1,259 shares of Janux Therapeutics worth $30.8K as of Q3 2025.
  • Janux Therapeutics was a new Point72 Europe position in Q3 2025.
  • Janux Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #425 holding.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.